MARKET

ABBV

ABBV

AbbVie
NYSE

Real-time Quotes | Nasdaq Last Sale

85.91
-1.23
-1.41%
After Hours: 86.13 +0.22 +0.26% 19:04 09/24 EDT
OPEN
87.00
PREV CLOSE
87.14
HIGH
87.00
LOW
85.32
VOLUME
9.98M
TURNOVER
--
52 WEEK HIGH
101.28
52 WEEK LOW
62.55
MARKET CAP
151.62B
P/E (TTM)
18.90
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Aerie' Roclanda on par with Allergan's Ganfort in glaucoma study
Aerie Pharmaceuticals (AERI) has announced interim 90-day topline data from its six-month Phase 3b (Mercury 3) trial in Europe, comparing Roclanda to Allergan's (ABBV) Ganfort for intraocular pressure ((IOP)) reduction in patients with open-angle
Seekingalpha · 16h ago
4 Dividend Growth Opportunities To Benefit From Market Decline
Stocks are on sale. Yet many allow emotions to get in the way of their investing success.Research shows that the best long-term investing strategy is to invest when you have the money. Avoid market timing.I neither have the time nor energy to track my investments constantly. I look for solid dividend growth companies I can buy and forget about.I've identified four dividend growth companies that are currently trading 12-34% below their YTD highs and are worthy of further consideration.
Seekingalpha · 1d ago
PEY Yourself More Or Lower Your Volatility With SPHD?
PEY and SPHD each offer investors about a 5% yield for their money.Which fund is better aligned with your investing goals?Personal diligence on the names in the funds, and beyond, offers investors and opportunity to earn higher returns.
Seekingalpha · 1d ago
These cheap stocks could see huge gains during a vaccine-driven economic rebound
When analysts raise their earnings estimates, shares of some of the hardest-hit companies will begin to bounce back.
marketwatch.com · 2d ago
AbbVie: I Don't Wanna Miss This Thing
2020 is shaping up to be another record year for AbbVie.Six months into the pandemic, AbbVie has mastered the crisis better than expected and once again demonstrated the power of its strong and resilient portfolio.AbbVie is undergoing a massive transformation from a product and organizational perspective.AbbVie is well-positioned for the future with a growing dividend, reasonable debt repayment, a strong pipeline and a healthy portfolio of successful drugs.AbbVie is a top dividend pick with its high, growing and secure dividend.
Seekingalpha · 2d ago
The Daily Biotech Pulse: Legal Relief For Evolus, Fulgent to Join S&P SmallCap 600, AIM ImmunoTech's Positive Cancer Drug Readout
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 21)
Benzinga · 2d ago
General Motors, Prudential, and 8 Other Cheap Big-Cap Stocks Worth a Look
These companies, with a market value of $10 billion or more, have some of the lowest P/E ratios.
Barrons.com · 2d ago
AbbVie (ABBV) Stock Moves -1.13%: What You Should Know
AbbVie (ABBV) closed the most recent trading day at $89.09, moving -1.13% from the previous trading session.
Zacks · 3d ago
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ABBV. Analyze the recent business situations of AbbVie through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 18 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ABBV stock price target is 109.81 with a high estimate of 127.00 and a low estimate of 96.00.
EPS
Institutional Holdings
Institutions: 2.21K
Institutional Holdings: 1.06B
% Owned: 59.93%
Shares Outstanding: 1.76B
TypeInstitutionsShares
Increased
882
76.24M
New
116
9.26M
Decreased
746
77.32M
Sold Out
112
1.89M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.83%
Pharmaceuticals & Medical Research
-0.82%
Key Executives
Chairman/Chief Executive Officer/Director
Richard Gonzalez
President/Vice Chairman - Management
Michael Severino
Vice Chairman - Management
Carlos Alban
Vice Chairman - Management
Laura Schumacher
Chief Financial Officer/Senior Vice President
Robert Michael
Chief Human Resource Officer/Executive Vice President
Timothy Richmond
Executive Vice President - Finance
William Chase
Executive Vice President
Henry Gosebruch
Executive Vice President
Azita Saleki-Gerhardt
Senior Vice President
Nicholas Donoghoe
Senior Vice President
Jeffrey Stewart
Vice President/Controller
Brian Durkin
Lead Director/Independent Director
Glenn Tilton
Independent Director
Robert Alpern
Independent Director
Roxanne Austin
Independent Director
William Burnside
Independent Director
Thomas Freyman
Independent Director
Brett Hart
Independent Director
Edward Liddy
Independent Director
Melody Meyer
Independent Director
Edward Rapp
Independent Director
Rebecca Roberts
Independent Director
Frederick Waddell
  • Dividends
  • Splits
  • Insider Activity
Declaration Date
Dividend Per Share
Ex-Div Date
09/11/2020
Dividend USD 1.18
10/14/2020
06/17/2020
Dividend USD 1.18
07/14/2020
02/20/2020
Dividend USD 1.18
04/14/2020
11/01/2019
Dividend USD 1.18
01/14/2020
09/06/2019
Dividend USD 1.07
10/11/2019
06/20/2019
Dividend USD 1.07
07/12/2019
02/21/2019
Dividend USD 1.07
04/12/2019
11/02/2018
Dividend USD 1.07
01/14/2019
09/07/2018
Dividend USD 0.96
10/12/2018
06/14/2018
Dividend USD 0.96
07/12/2018
02/15/2018
Dividend USD 0.96
04/12/2018
10/26/2017
Dividend USD 0.71
01/11/2018
09/08/2017
Dividend USD 0.64
10/12/2017
06/23/2017
Dividend USD 0.64
07/12/2017
02/17/2017
Dividend USD 0.64
04/11/2017
10/31/2016
Dividend USD 0.64
01/11/2017
09/09/2016
Dividend USD 0.57
10/12/2016
06/16/2016
Dividend USD 0.57
07/13/2016
02/18/2016
Dividend USD 0.57
04/13/2016
10/30/2015
Dividend USD 0.57
01/13/2016
09/11/2015
Dividend USD 0.51
10/13/2015
06/19/2015
Dividend USD 0.51
07/13/2015
02/19/2015
Dividend USD 0.51
04/13/2015
10/21/2014
Dividend USD 0.49
01/13/2015
09/19/2014
Dividend USD 0.42
10/10/2014
06/19/2014
Dividend USD 0.42
07/11/2014
02/20/2014
Dividend USD 0.42
04/11/2014
12/12/2013
Dividend USD 0.4
01/13/2014
09/19/2013
Dividend USD 0.4
10/10/2013
06/20/2013
Dividend USD 0.4
07/11/2013
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About ABBV
AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions. It offers products in various categories, including HUMIRA (adalimumab), Oncology products, Virology Products, Additional Virology products, Metabolics/Hormones products, Endocrinology products and other products, which include Duopa and Duodopa (carbidopa and levodopa), Anesthesia products and ZINBRYTA (daclizumab).
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of AbbVie Inc stock information, including NYSE:ABBV real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ABBV stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ABBV stock methods without spending real money on the virtual paper trading platform.